Skip to content

Inspection Record

GH Genhelix, S.A. — FDA 483 Findings

US FDAInspected 2022-01-25Published 2026-10-23 9 findingsTraining and personnelLaboratory and QC controlsEquipment and facilityOther quality systemMaterial and supplier controlStability and storageDeviation, CAPA, and investigation

Inspectors Arsen KarapetyanThe inspectors who signed the published document.Inspector lookup

View the regulator's official source The source document is always the basis for judgement.

Findings

1Training and personnel

a) The instructions to add antifoam in the production bioreactor are unclear and open to operator interpretation.

2Laboratory and QC controls

The responsibilities and procedures applicable to the quality control are not in writing and fully followed.

3Equipment and facility

Equipment used in the manufacture and processing of a drug substance shall be suitably located to facilitate operations for its intended use.

4Other quality system

Class D area cleaning is inadequate.

5Material and supplier control

Material Management is inadequate.

6Other quality system

Drug Substance filling is inadequate.

7Stability and storage

Cell Bank Storage is inadequate.

8Other quality system

havens cleaning is inadequate.

9Deviation, CAPA, and investigation

Written records of investigations into unexplained discrepancies do not always include conclusions and follow-up which are adequately justified.

Similar findings at other companies

GRM selected findings from the same type of public document whose wording is close to a finding in this document. One per company.

A record as of the US FDA document published on 2026-10-23. Check the agency's announcements for any later corrective action, and rely on the original text. Translation and classification are machine-made.

GH Genhelix, S.A. company profile — full historyAll US FDA findings US FDA documents, 2026 Go to Findings search
Linked from (backlinks)
Briefs that featured this document
Weekly Newsletter

Get new findings like these every Monday

Every Monday we email the week's new findings and actions from the FDA, EMA, Health Canada and MFDS. Each one links to its record on our site, where you'll find the regulator's original document. We'll also let you know when the site gains new features. Unsubscribe any time with one click.

See recent findings first

Sent every Monday · a confirmation email follows when you subscribe · unsubscribe from the footer of any email.